[go: up one dir, main page]

MA50752A - Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation - Google Patents

Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation

Info

Publication number
MA50752A
MA50752A MA050752A MA50752A MA50752A MA 50752 A MA50752 A MA 50752A MA 050752 A MA050752 A MA 050752A MA 50752 A MA50752 A MA 50752A MA 50752 A MA50752 A MA 50752A
Authority
MA
Morocco
Prior art keywords
methods
drug conjugates
antibody drug
activable antibody
antibodies
Prior art date
Application number
MA050752A
Other languages
English (en)
Other versions
MA50752B1 (fr
Inventor
Ilaria Badagnani
Sahana Bose
Tracy Henriques
Marvin Robert Leanna
Susan E Morgan-Lappe
Sherry L Ralston
Jennifer Hope Richardson
Laura Patterson Serwer
Shweta Singh
Jonathan Alexander Terrett
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MA50752A publication Critical patent/MA50752A/fr
Publication of MA50752B1 publication Critical patent/MA50752B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne d'une manière générale des anticorps qui se lient spécifiquement à cd71 dans leur forme active et des procédés de réalisation et d'utilisation de ces anticorps anti-cd711 activables conjugués dans une variété d'indications thérapeutiques, diagnostiques et prophylactiques.
MA50752A 2017-10-14 2018-10-12 Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation MA50752B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762572467P 2017-10-14 2017-10-14
PCT/US2018/055733 WO2019075417A1 (fr) 2017-10-14 2018-10-12 Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA50752A true MA50752A (fr) 2020-08-12
MA50752B1 MA50752B1 (fr) 2021-03-31

Family

ID=64110112

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50752A MA50752B1 (fr) 2017-10-14 2018-10-12 Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation

Country Status (36)

Country Link
US (3) US20190111150A1 (fr)
EP (2) EP3691692B8 (fr)
JP (2) JP7374891B2 (fr)
KR (4) KR102529359B1 (fr)
CN (1) CN111278467B (fr)
AR (1) AR115178A1 (fr)
AU (1) AU2018346969A1 (fr)
BR (1) BR112020007302B1 (fr)
CA (1) CA3077730A1 (fr)
CL (1) CL2020000977A1 (fr)
CO (1) CO2020005685A2 (fr)
CR (1) CR20200206A (fr)
CY (1) CY1123968T1 (fr)
DK (1) DK3691692T3 (fr)
DO (1) DOP2023000150A (fr)
EC (1) ECSP20025198A (fr)
ES (1) ES2864013T3 (fr)
HR (1) HRP20210436T8 (fr)
HU (1) HUE054037T2 (fr)
IL (1) IL273586A (fr)
LT (1) LT3691692T (fr)
MA (1) MA50752B1 (fr)
MD (1) MD3691692T2 (fr)
MX (1) MX2020003723A (fr)
PE (1) PE20210125A1 (fr)
PH (1) PH12020550417A1 (fr)
PL (1) PL3691692T3 (fr)
PT (1) PT3691692T (fr)
RS (1) RS61596B1 (fr)
RU (2) RU2022111211A (fr)
SG (1) SG11202003378WA (fr)
SI (1) SI3691692T1 (fr)
SM (1) SMT202100184T1 (fr)
TW (2) TW202330039A (fr)
UY (1) UY37931A (fr)
WO (1) WO2019075417A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
MY194184A (en) * 2015-05-04 2022-11-17 Cytomx Therapeutics Inc Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
EP3635009A1 (fr) 2017-06-07 2020-04-15 Regeneron Pharmaceuticals, Inc. Compositions et méthodes pour l'internalisation d'enzymes
CN111278467B (zh) * 2017-10-14 2024-07-30 艾伯维公司 抗cd71可活化抗体药物缀合物和其使用方法
IL322464A (en) 2018-02-07 2025-09-01 Regeneron Pharma Methods and compositions for administering therapeutic protein
WO2019183633A1 (fr) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Composés conjugués ciblés sur le psma et leurs utilisations
EP3793591A1 (fr) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anticorps anti-cd63, conjugués et leurs utilisations
IL297148A (en) * 2020-04-08 2022-12-01 Janssen Biotech Inc Compositions and methods for blood-brain barrier delivery
AU2021254279A1 (en) * 2020-04-09 2022-11-10 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
CN116194470B (zh) * 2020-07-23 2025-10-03 达因疗法公司 肌肉靶向复合物及其用途
US20250332265A1 (en) 2021-11-09 2025-10-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
KR20250054842A (ko) * 2022-07-29 2025-04-23 리제너론 파마슈티칼스 인코포레이티드 뇌 및 근육으로의 트랜스페린 수용체(tfr)-매개 전달을 위한 조성물 및 방법
WO2025024334A1 (fr) 2023-07-21 2025-01-30 Marrow Therapeutics, Inc. Conjugués de ciblage de cellules hématopoïétiques et procédés associés
WO2025133132A1 (fr) * 2023-12-20 2025-06-26 Institut National De La Sante Et De La Recherche Medicale Nouveaux anticorps anti-tfr1 (cd71) pour le traitement du cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001513A1 (fr) 1986-08-28 1988-03-10 Teijin Limited Complexe d'anticorps cytocide et procede de production
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
EP1919931A4 (fr) 2005-08-31 2010-01-20 Univ California Bibliotheques cellulaires de sequences peptidiques (clips) et procedes d'utilisation de celles-ci
JP6035009B2 (ja) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
DK2224954T3 (en) * 2007-11-07 2014-03-03 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP3543256A1 (fr) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Compositions d anticorps modifiées et leurs procédés de production et d'utilisation
EP2424891B1 (fr) * 2009-04-29 2014-06-11 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Anticorps erg monoclonaux
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
MX350200B (es) * 2011-02-01 2017-08-30 Genmab As Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
US9944715B2 (en) * 2012-01-31 2018-04-17 Sbi Biotech Co., Ltd. Anti-phospholipase D4 antibody
EP2882844B1 (fr) 2012-08-10 2018-10-03 Cytomx Therapeutics Inc. Systèmes résistant aux protéases pour présentation de polypeptides, leurs procédés de préparation et utilisation
CN103145847B (zh) * 2013-02-05 2014-05-21 浙江大学 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
IL320281A (en) * 2013-12-25 2025-06-01 Daiichi Sankyo Co Ltd Anti-trop2 antibodies and methods for producing same
MY194184A (en) * 2015-05-04 2022-11-17 Cytomx Therapeutics Inc Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
CN106237341B (zh) * 2016-07-12 2019-07-30 浙江大学 一种抗体偶联药物及其制备方法和应用
CN111278467B (zh) * 2017-10-14 2024-07-30 艾伯维公司 抗cd71可活化抗体药物缀合物和其使用方法

Also Published As

Publication number Publication date
PE20210125A1 (es) 2021-01-19
BR112020007302B1 (pt) 2023-01-31
RU2020115713A (ru) 2021-11-16
AR115178A1 (es) 2020-12-09
KR102385495B1 (ko) 2022-04-15
EP3691692B1 (fr) 2020-12-30
WO2019075417A1 (fr) 2019-04-18
US20240115724A1 (en) 2024-04-11
PT3691692T (pt) 2021-03-29
KR20200070324A (ko) 2020-06-17
ECSP20025198A (es) 2020-06-30
RU2771292C2 (ru) 2022-04-29
KR102529359B1 (ko) 2023-05-09
BR112020007302A2 (pt) 2020-09-29
RU2022111211A (ru) 2022-05-05
CN111278467B (zh) 2024-07-30
CY1123968T1 (el) 2022-05-27
EP3834846A1 (fr) 2021-06-16
EP3691692A1 (fr) 2020-08-12
CO2020005685A2 (es) 2020-05-15
HRP20210436T1 (hr) 2021-04-30
HRP20210436T8 (hr) 2022-01-07
CL2020000977A1 (es) 2020-09-11
EP3691692B8 (fr) 2021-05-26
SMT202100184T1 (it) 2021-05-07
LT3691692T (lt) 2021-05-10
TWI780237B (zh) 2022-10-11
AU2018346969A1 (en) 2020-04-23
UY37931A (es) 2019-04-30
SG11202003378WA (en) 2020-05-28
JP7374891B2 (ja) 2023-11-07
RS61596B1 (sr) 2021-04-29
SI3691692T1 (sl) 2021-04-30
KR20220045088A (ko) 2022-04-12
US20210145978A1 (en) 2021-05-20
DOP2023000150A (es) 2023-08-31
MA50752B1 (fr) 2021-03-31
JP2020537649A (ja) 2020-12-24
CA3077730A1 (fr) 2019-04-18
CN111278467A (zh) 2020-06-12
US20190111150A1 (en) 2019-04-18
HUE054037T2 (hu) 2021-08-30
MX2020003723A (es) 2020-07-22
KR20230070046A (ko) 2023-05-19
PL3691692T3 (pl) 2021-07-19
TW202330039A (zh) 2023-08-01
IL273586A (en) 2020-05-31
TW201927815A (zh) 2019-07-16
DK3691692T3 (da) 2021-03-22
MD3691692T2 (ro) 2021-05-31
CR20200206A (es) 2021-02-18
ES2864013T3 (es) 2021-10-13
PH12020550417A1 (en) 2021-04-12
KR20230004932A (ko) 2023-01-06
JP2024012366A (ja) 2024-01-30
RU2020115713A3 (fr) 2022-02-25

Similar Documents

Publication Publication Date Title
MA50752A (fr) Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
MA39909B1 (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
WO2019014328A3 (fr) Anticorps agonistes qui lient cd137 humain et leurs utilisations
CR20120505A (es) Composición de fármaco conjugado
CL2019002250A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520)
MA53330A (fr) Constructions d'anticorps pour cldn18.2 et cd3
EP3783025A4 (fr) Anticorps cd73 ciblé et conjugué anticorps-médicament, procédé de préparation associé et utilisations correspondantes
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CR10273A (es) "anticuerpos anti-5t4 y usos de los mismos"
MA47664B1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA31984B1 (fr) Formulation d'anticorps
CR8317A (es) Anticuerpos dirigidos a m-csf
SA519401647B1 (ar) y مركبات ببتيد تيروسين-تيروسين الحلقية المقترنة بجسم مضاد كمعدلات لمستقبلات الببتيد العصبي
ATE391174T1 (de) Modifizierter tpo-agonisten antikörper
CL2012001853A1 (es) Formulación farmacéutica que comprende un anticuerpo humano que se une de modo especifico al receptor de interleuquina 6 humana (hil-6r), histidina y un carbohidrato.
MA29975B1 (fr) Antagonistes de la neuropiline
BR112022011032A2 (pt) Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo
MA31793B1 (fr) Nouveaux anticorps specifiques de peptides beta- amyloides et leurs utilisations comme agents diagnostiques ou medicaments
CR11399A (es) ANTICUERPOS ANTI-IL-12/23p40, EPITOPES, FORMULACIONES, COMPOSICIONES, METODOS Y USOS
MA37407A1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
MA37946B1 (fr) Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde